The DOI matches its Crossref record; 267 of the 267 references it cites were found in a registry or an index.
Erythropoietin or darbepoetin for patients with cancer
Open accessAbstract
BACKGROUND: Anaemia associated with cancer and cancer therapy is an important clinical factor in the treatment of malignant diseases. Therapeutic alternatives are recombinant human erythropoiesis stimulating agents (ESAs) and red blood cell transfusions. OBJECTIVES: To assess the effects of ESAs to either prevent or treat anaemia in cancer patients. SEARCH METHODS: This is an update of a Cochrane review first published in 2004. We searched the Central Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE and other databases. Searches were done for the periods 01/1985 to 12/2001 for the first review, 1/2002 to 04/2005 for the first update and to November 2011 for the current update. We also contacted experts in the field and pharmaceutical companies. SELECTION CRITERIA: Randomised controlled trials on managing anaemia in cancer patients receiving or not receiving anti-cancer therapy that compared the use of ESAs (plus transfusion if needed). DATA COLLECTION AND ANALYSIS: Several review authors assessed trial quality and extracted data. One review author assessed quality assessment and extracted data, a second review author checked for correctness. MAIN RESULTS: This update of the systematic review includes a total of 91 trials with 20,102 participants. Use of ESAs significantly reduced the relative risk of red blood cell transfusions (risk ratio (RR) 0.65; 95% confidence interval (CI) 0.62 to 0.68, 70 trials, N = 16,093). On average, participants in the ESAs group received one unit of blood less than the control group (mean difference (MD) -0.98; 95% CI -1.17 to -0.78, 19 trials, N = 4,715). Haematological response was observed more often in participants receiving ESAs (RR 3.93; 95% CI 3.10 to 3.71, 31 trials, N = 6,413). There was suggestive evidence that ESAs may improve Quality of Life (QoL). There was strong evidence that ESAs increase mortality during active study period (hazard ratio (HR) 1.17; 95% CI 1.06 to 1.29, 70 trials, N = 15,935) and some evidence that ESAs decrease overall survival (HR 1.05; 95% CI 1.00 to 1.11, 78 trials, N = 19,003). The risk ratio for thromboembolic complications was increased in patients receiving ESAs compared to controls (RR 1.52, 95% CI 1.34 to 1.74; 57 trials, N = 15,498). ESAs may also increase the risk for hypertension (fixed-effect model: RR 1.30; 95% CI 1.08 to 1.56; random-effects model: RR 1.12; 95% CI 0.94 to 1.33, 31 trials, N = 7,228) and thrombocytopenia/haemorrhage (RR 1.21; 95% CI 1.04 to 1.42; 21 trials, N = 4,507). There was insufficient evidence to support an effect of ESA on tumour response (fixed-effect RR 1.02; 95% CI 0.98 to 1.06, 15 trials, N = 5,012). AUTHORS' CONCLUSIONS: ESAs reduce the need for red blood cell transfusions but increase the risk for thromboembolic events and deaths. There is suggestive evidence that ESAs may improve QoL. Whether and how ESAs affects tumour control remains uncertain. The increased risk of death and thromboembolic events should be balanced against the potential benefits of ESA treatment taking into account each patient's clinical circumstances and preferences. More data are needed for the effect of these drugs on quality of life and tumour progression. Further research is needed to clarify cellular and molecular mechanisms and pathways of the effects of ESAs on thrombogenesis and their potential effects on tumour growth.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–267 of 267
Aapro, M., Cella, D. F., & Zagari, M. J. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.33534 · Cited by 42
The Effect of Epoetin alfa on Quality of Life in Anemic Cancer Patients
Cella, D. F., & Bron, D. (1999) · Cancer Practice · doi:10.1046/j.1523-5394.1999.74008.x · Cited by 41
Erythropoietin Use in Cancer Patients: A Matter of Life and Death?
Steensma, D. P., & Loprinzi, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.036 · Cited by 41
Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer.
Welch, R., James, R. D., Wilkinson, P. M., et al. (2006) · PubMed · Cited by 40
Iconomou, G., Koutras, A. K., Rigopoulos, A., Vagenakis, A. G., & Kalofonos, H. P. (2003) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(03)00070-8 · Cited by 40
Non-erythroid effects of erythropoietin
Arcasoy, M. O. (2010) · Haematologica · doi:10.3324/haematol.2010.030213 · Cited by 40
The Effect of Alterations in Haematocrit on Tumour Sensitivity to X-rays
Hirst, D. G., Hazlehurst, J. L., & Brown, J. M. (1984) · International Journal of Radiation Biology and Related Studies in Physics Chemistry and Medicine · doi:10.1080/09553008414551521 · Cited by 40
Fairclough, D. L., Gagnon, D. D., Zagari, M. J., Marschner, N. W., & Dicato, M. A. (2003) · Quality of Life Research · doi:10.1023/a:1026116426494 · Cited by 39
A new concept for the differential diagnosis and therapy of anaemia in cancer patients
Steinmetz, H. T., Tsamaloukas, A. G., Schmitz, S. H., Wiegand, J., Rohrberg, R., Eggert, J., Breuer, F., Tessen, H.-W., Eustermann, H., & Thomas, L. (2010) · Supportive Care in Cancer · doi:10.1007/s00520-010-0812-2 · Cited by 38
Meta-analyses of the effectiveness of erythropoietin for end-stage renal disease and cancer
Marsh, W. A., & Rascati, K. L. (1999) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)80003-x · Cited by 38
Wagner, L. M., Billups, C. A., Furman, W. L., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.002 · Cited by 33
Charu, V., Belani, C. P., Gill, A. N., Bhatt, M., Tomita, D. K., Rossi, G., & Ben-Jacob, A. (2007) · The Oncologist · doi:10.1634/theoncologist.12-6-727 · Cited by 33
Pronzato, P., Cortesi, E., van der Rijt, C. C. D., Bols, A., Moreno-Nogueira, J. A., Oliveira, C., Barrett-Lee, P. J., Ostler, P. J., Rosso, R., & EPO-INT-47 Study Group (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0279 · Cited by 33
Anemia in Cervical Cancer Patients: Implications for Iron Supplementation Therapy
Candelaria, M., Cetina, L., & Dueñas‐González, A. (2005) · Medical Oncology · doi:10.1385/mo:22:2:161 · Cited by 32
Katodritou, E., Verrou, E., Hadjiaggelidou, C., Gastari, V., Laschos, Κ., Kontovinis, L., Kapetanos, D., Constantinou, N., Terpos, E., & Zervas, K. (2008) · American Journal of Hematology · doi:10.1002/ajh.21239 · Cited by 31
Tsuboi, M., Ezaki, K., Tobinai, K., Ohashi, Y., & Saijo, N. (2009) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyn151 · Cited by 29
Vekeman, F., Bookhart, B., White, J. T., et al. (2009) · Transfusion · doi:10.1111/j.1537-2995.2008.02072.x · Cited by 28
Impact of dose frequency on compliance and health outcomes: a literature review (1966–2006)
Shi, L., Hodges, M., Yurgin, N., & Boye, K. S. (2007) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.7.2.187 · Cited by 28
Senecal, F. M., Yee, L., Gabrail, N. Y., Charu, V., Tomita, D. K., Rossi, G., & Schwartzberg, L. S. (2005) · Clinical Breast Cancer · doi:10.3816/cbc.2005.n.050 · Cited by 27
Bennett, C. L., Lai, S. Y., Henke, M., Barnato, S. E., Armitage, J. O., & Sartor, O. A. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.309 · Cited by 26
Chang, J., Couture, F., Young, S. D., Lau, C. Y., & McWatters, K. (2004) · Supportive Cancer Therapy · doi:10.3816/sct.2004.n.023 · Cited by 26
A Risk-Benefit Assessment of Epoetin in the Management of Anaemia Associated with Cancer
Beguin, Y. (1998) · Drug Safety · doi:10.2165/00002018-199819040-00003 · Cited by 25
Erythropoietin for oncology supportive care
McKinney, M. S., & Arcasoy, M. O. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.03.003 · Cited by 25
Erythropoietin Treatment in Metastatic Breast Cancer
Olsson, A.-M., Svensson, J.-H., Sundström, J., Bergström, S. N., Edekling, T., Carlsson, G. U., Hansen, J., Svensson, B., & Albertsson, M. (2002) · Acta Oncologica · doi:10.1080/02841860214960 · Cited by 25
Therapeutic effects of epoetin zeta in the treatment of chemotherapy-induced anaemia
Tzekova, V., Mihaylov, G. G., Elezović, I. V., Koytchev, R., & on behalf of the Epoetin Zeta Oncology Study Group (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903050876 · Cited by 24
Gordon, D., NICHOLS, G. L., Ben-Jacob, A., Tomita, D. K., Lillie, T., & Miller, C. B. (2008) · The Oncologist · doi:10.1634/theoncologist.2007-0241 · Cited by 24
Hernández, E., Ganly, P. S., Charu, V., DiBenedetto, J., Tomita, D. K., Lillie, T., Taylor, K. M., & for the ARANESP 20030232 Study Group (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903084164 · Cited by 23
Implications of the Anemia of Chronic Disorders in Patients Anticipating Radiotherapy
Reed, W. R., Hussey, D. H., & DeGowin, R. L. (1994) · The American Journal of the Medical Sciences · doi:10.1097/00000441-199407000-00004 · Cited by 23
Erythropoietin in Radiation Oncology – A Review
Henke, M., & Guttenberger, R. (2000) · Oncology · doi:10.1159/000012096 · Cited by 22
Erythropoiesis stimulating agents, thrombosis and cancer
Barbera, L. C., & Thomas, G. (2010) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2010.02.008 · Cited by 22
Joiner, B., Hirst, V. K., McKeown, S., McAleer, J. J., & Hirst, D. G. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.417 · Cited by 22
Nowrousian, M. R. (2008) · Springer eBooks · doi:10.1007/978-3-211-69459-6 · Cited by 22
Tjulandin, S., Bias, P., Elsässer, R., Gertz, B., Kohler, E., & Buchner, A. (2010) · Archives of Drug Information · doi:10.1111/j.1753-5174.2010.00030.x · Cited by 21
Merchionne, F., & Dammacco, F. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07702.x · Cited by 20
Latagliata, R., Olíva, E. N., Volpicelli, P., Carmosino, I., Breccia, M., Vincelli, I. D., Alati, C., Napoleone, L., Vozella, F., Nobile, F., et al. (2008) · Acta Haematologica · doi:10.1159/000166864 · Cited by 19
Increased autologous blood donation in rectal cancer by recombinant human erythropoietin (rhEPO)
Rau, B., Schlag, P. M., Willeke, F., Herfarth, C., Stephan, P., & Franke, W. W. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00021-5 · Cited by 17
Glossmann, J.-P., Engert, A., Wassmer, G., Flechtner, H., Ko, Y. H., Rudolph, C., Metzner, B., Dörken, B., Wiedenmann, S., Diehl, V., et al. (2003) · Annals of Hematology · doi:10.1007/s00277-003-0695-0 · Cited by 17
Self-citationMorishima, Y., Ogura, M., Yoneda, S., Sakai, H., Tobinai, K., Nishiwaki, Y., Minami, H., Hotta, T., Ezaki, K., Ohe, Y., et al. (2006) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyl097 · Cited by 17
Justice, G. R., Kessler, J. F., Jadeja, J., Campos, L. T., Weick, J. K., Chen, C.-F., Heatherington, A. C., & Amado, R. G. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi218 · Cited by 16
Richardson, P. G. G., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M. H., Vekemans, M., Petrucci, M. T., Rossiev, V. A., Hou, J., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08569.x · Cited by 15
Boccia, R. V., Lillie, T., Tomita, D. K., & Balducci, L. (2007) · The Oncologist · doi:10.1634/theoncologist.12-5-584 · Cited by 15
Nagel, S., Kellner, O., Engel-Riedel, W., Guetz, S., Schumann, C., Gieseler, F., & Schuette, W. (2011) · Clinical Lung Cancer · doi:10.3816/clc.2011.n.009 · Cited by 14
Anthony, L. B., Gabrail, N. Y., Ghazal, H., Woytowitz, D., Flam, M. S., Drelichman, A., Loesch, D. M., Niforos, D., & Mangione, A. (2011) · Community Oncology · doi:10.1016/s1548-5315(12)70022-0 · Cited by 13
Henry, D. H., Dahl, N. V., & Auerbach, M. (2007) · Blood · doi:10.1182/blood.v110.11.1625.1625 · Cited by 13
Borg, S., Glenngård, A., Österborg, A., & Persson, U. (2008) · Acta Oncologica · doi:10.1080/02841860701744498 · Cited by 12
Lönnroth, C., Svensson, M. K., Wang, W., Körner, U., Daneryd, P., Nilsson, O., & Lundholm, K. (2007) · Medical Oncology · doi:10.1007/s12032-007-9001-7 · Cited by 11
Gebbia, V., Marco, P. D., & Citarrella, P. (2003) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2003.07.002 · Cited by 11
Stull, D. E., Vernon, M., Legg, J. C., Viswanathan, H. N., Fairclough, D. L., & Revicki, D. A. (2010) · Contemporary Clinical Trials · doi:10.1016/j.cct.2009.12.006 · Cited by 11
Mel, J. R., Salar, A., Rodriguez, C. A., Alegre, A. M., González, A., Cassinello, J., Montesinos, J., Gasquet, J. A., Sánchez, J., Saigí, E., et al. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802381323 · Cited by 10
Gregory, S. A. (2006) · Supportive Cancer Therapy · doi:10.3816/sct.2006.n.021 · Cited by 10
Kotasek, D., Canon, J.-L. R., Mateos, M., Hedenus, M., Rossi, G., & Taylor, K. M. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x188053 · Cited by 9
Erythropoietin as a cardioprotective agent: down but not out
Opie, L. H. (2011) · Heart · doi:10.1136/heartjnl-2011-300411 · Cited by 8
Epoetin Delta: Efficacy in the Treatment of Anaemia in Cancer Patients Receiving Chemotherapy
Krzakowski, M. J. (2008) · Clinical Oncology · doi:10.1016/j.clon.2008.06.001 · Cited by 8
Erythropoietin and cancer, a double-edged sword
Ribatti, D. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.06.004 · Cited by 8
Nowrousian, M. R. (2002) · Springer eBooks · doi:10.1007/978-3-7091-7658-0_4 · Cited by 8
VTE and mortality associated with erythropoiesis-stimulating agents in cancer-associated anemia
Dronca, R. S., & Steensma, D. P. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1202 · Cited by 7
Kim, T., Kim, K., Kim, B., Shin, S.-G., Jang, I., & Yu, K. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.10.001 · Cited by 6
Flexible dosing with Darbepoetin alfa for the treatment of chemotherapy-induced anemia
Wauters, I., Pat, K., & Vansteenkiste, J. (2006) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.2006.2.2.175 · Cited by 4
Erythropoiesis-stimulating agents in myelodysplastic syndromes
Hellström‐Lindberg, E. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.496020 · Cited by 4
Loibl, S., Kaufmann, M., Maataoui, V., Mehta, K. M., Hofmann, K., Petrich, S., & von Minckwitz, G. (2006) · Supportive Cancer Therapy · doi:10.3816/sct.2006.n.006 · Cited by 4
Qualité de vie et transfusion en cancérologie: revue de la littérature
Poirier, A.-L., Commer, J., Kwiatkowski, F., Mercier, M., & Bonnetain, F. (2010) · Transfusion Clinique et Biologique · doi:10.1016/j.tracli.2010.09.162 · Cited by 4
Epoetins and mortality in patients with cancer
Nonoguchi, H., Otaki, Y., Tokuyama, M., Yamamoto, S., & Nakanishi, T. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61356-8 · Cited by 3
Ots, P. S., Carrizosa, C. L., Pérez, A. R., Garrido, J. D. D. S., & Pérez, J. M. D. (2008) · Clinical medicine Oncology · doi:10.4137/cmo.s510 · Cited by 2
Treatment of anemia by recombinant human erythropoietin in cancer patients undergoing radiotherapy
Yurut‐Caloglu, V., & Çaloğlu, M. (2008) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/j.1743-7563.2008.00217.x · Cited by 2
Mustacchi, G., Ceccherini, R., Dellach, C., Foladore, S., Milani, S., Leita, M. L., & Sisto, M. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl297 · Cited by 1
Walsh (1995) · doi:10.1002/1097-0142(19951201)76:11
Explaining heterogeneity in meta-analysis: a comparison of methods
Thompson, S. G., & Sharp, S. J. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19991030)18:20
Cited by
Batchelor, T. J. P., Rasburn, N. J., Abdelnour-Berchtold, E., Brunelli, A., Cerfolio, R. J., Gonzalez, M., Ljungqvist, O., Petersen, R. H., Popescu, W. M., Slinger, P. D., et al. (2019) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezy301 · Cited by 1,366
Weiss, G., Ganz, T., & Goodnough, L. T. (2019) · Blood · doi:10.1182/blood-2018-06-856500 · Cited by 1,219
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications
Terpos, E., Kleber, M., Engelhardt, M., Zweegman, S., Gay, F., Kastritis, E., van de Donk, N. W. C. J., Bruno, B., Sezer, O., Broijl, A., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.117176 · Cited by 988
Bennett, C. L. (2008) · JAMA · doi:10.1001/jama.299.8.914 · Cited by 731
Nelson, G., Altman, A. D., Nick, A., Meyer, L. A., Ramirez, P. T., Achtari, C., Antrobus, J., Huang, J., Scott, M., Wijk, L., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.12.019 · Cited by 562
Metadata
- Authors
- Tonia, T., Mettler, A., Robert, N., Schwarzer, G., Seidenfeld, J., Weingart, O., Hyde, C., Engert, A., & Bohlius, J.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2012-12-12
- Volume
- 2012
- Issue
- 12
- Pages
- CD003407-CD003407
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2111324822
- Cited by
- 392
- References
- 267
- FWCI
- 18.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.